INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Bachrodt Amy sold MAZE

SVP, Finance · Maze Therapeutics, Inc. · Common Stock

Side
SELL
Value
$25K
Shares
600
Price
$41.16
Executed
Dec 29, 2025
Disclosed
Dec 31, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Dec 29 executedDec 31, 2025 disclosed

MAZE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+1 / 25

    $25K reported value · 4.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MAZE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    16
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$799K
    26.6K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$166K
    5,345 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$68K
    2,257 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    6
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$10K
    336 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    6,643 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    3
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$69K
    6,643 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    10
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$241K
    7,500 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    857 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$8,930
    857 sh
    		Oct 29, 2026Oct 30, 2026
    traded Oct 29, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$168K
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    21
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$435K
    16.1K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    10
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$203K
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    0
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M—
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    3
    DA
    Dandekar AtulCSBO
    MAZEMaze Therapeutics, Inc.
    Option exercise · 10b5-1 plan
    		M$78K
    7,500 sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    31
    BH
    Bernstein HaroldPresident, R&D & CMO
    MAZEMaze Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$255K
    9,705 sh
    		Sep 4, 2026Sep 8, 2026
    traded Sep 4, 2026
    		+4dSEC FORM 4

    Evidence

    46
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$260K
    9,852 sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    46
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$293K
    11.3K sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    36
    CP
    Courtney PhillipsGC and Corp. Secretary
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$6,590
    243 sh
    		Sep 2, 2026Sep 4, 2026
    traded Sep 2, 2026
    		+2dSEC FORM 4

    Evidence

    32
    CV
    Coloma Jason VDirector, Chief Executive Officer
    MAZEMaze Therapeutics, Inc.
    Open-market sale
    		SELL$3,325
    129 sh
    		Sep 3, 2026Sep 4, 2026
    traded Sep 3, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002050422-25-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 29, 2025
    Published
    Dec 31, 2025
    Ingested by INSIDER
    Nov 5, 04:25 UTC
    Last re-read
    Nov 5, 04:25 UTC

    Extracted facts

    Filer
    Bachrodt Amy
    Role
    SVP, Finance
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Maze Therapeutics, Inc.
    Ticker
    MAZE
    Shares
    600
    Price per share
    $41.16
    Value
    $24,695
    Execution date (reported)
    Dec 29, 2025
    Owned after transaction
    13.0K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 600
    • Price: $41.1583

    = $24,695

    What this establishes

    Bachrodt Amy filed this Form 4 reporting a open-market sale of MAZE on Dec 29, 2025. It became public on Dec 31, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Finance
    Bachrodt Amycik:0002050422
    Issuer
    Maze Therapeutics, Inc.cik:0001842295

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.